Objectives: People with a history of injecting drugs have high prevalence of hepatitis C virus (HCV) infection, and many have opioid use disorder (OUD). Modern HCV therapies with improved efficacy and tolerability are available, but access is often limited for this group, who may be underserved for health care and face social inequity. This work develops practical steps to improve HCV care in this population. Methods: Practical steps to improve HCV care in OUD populations were developed based on clinical experience from Spain, structured assessment of published evidence. Results: Options for improving care at engagement/screening stages include patient education programs, strong provider-patient relationship, peer support, and adoption of rapid effective screening tools. To facilitate work up/treatment, start options include simplified work up process, integration of HCV and OUD care, and continuous psychosocial support prior, during, and after HCV treatment.
Introduction
Chronic hepatitis C virus (HCV) infection is common in people with a history of injecting drugs and opioid use disorder (OUD). 1, 2 In Europe, it is estimated that 2-3 million individuals have a lifetime history of injecting drug use, including 1.5 million who have a recent history of OUD. 2 HCV infection is prevalent in 14-84% of such groups. 3 Despite high prevalence, individuals in these groups are often marginalized and have limited access to general health care. 4 Increasing mortality/morbidity due to advanced liver disease defines a major public health problem among people with a history of injecting drugs and OUD 5 and calls for enhanced access to HCV care for such a marginalized population. 6 Direct-acting antiviral (DAA) drugs indicated for HCV treatment, with improved efficacy, safety profile, and tolerability, when compared with interferon-based regimens, have transformed outcomes. 7 DAA regimens are effective in patients receiving opioid agonist therapy (OAT)/opioid substitution therapy (OST) for OUD. [8] [9] [10] Many people with a history of injecting drugs are engaged with OUD treatment services 11 ;
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Roncero et al in Europe, the proportion of engagement with OUD care is 40-90%. 12 In Spain, an estimated 60-80,000 people are engaged with OUD treatment services, 2 of whom 50-80% are infected with HCV. 2, 13 OUD care is often provided by social services, municipal authorities, or the national health service, in different settings within each region or country. 2, 12, 13 These centers are separated from potential points of care for HCV. 12 In Spain and other countries, OUD treatment is provided in specialist-led, often standalone offices or clinics; HCV specialist services are not co-located in many cases. 5, 12 Local arrangements for HCV management clinical services are the responsibility of different parts of the health care system, including infectious diseases, internal medicine, and hepatology departments. These organizational factors limit the success of HCV care; social and provider-related barriers to HCV care are also significant. 14 The objective of this work is to identify practical steps to improve HCV treatment in people with a history of injecting drugs and OUD based on clinical experience and relevant evidence in this evolving area.
Methods
Evidence describing interventions that may improve outcomes in the management of HCV treatment in the context of OUD was collected and assessed. A structured approach to organize analysis was followed, applying an existing framework of a patient journey. 2, 15 This framework describes treatment in steps from potential initial presentation at a drug treatment service through steps of engagement, screening, work up/referral, and treatment ( Figure 1 ).
Evidence collection
A structured search of published literature from PubMed, Web of Science, and Cochrane databases was completed using a set of predefined search terms ( Table 1) . The search was restricted to publications after 2012, when the first DAA medications became available. A specific additional search of the proceedings of recent, relevant scientific expert meetings was completed to capture the most recent evidence. This focused on the major academic congresses of the leading professional societies, as identified by experts highly familiar with the therapy area. These included American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), and British Association for the Study of the Liver (BASL). Two reviewers familiar with structured literature searches and the therapy area assessed evidence independently and analyzed data. A total of 597 articles (PubMed =457, Web of Science =110, and Cochrane =30) and 443 abstracts (AASLD 2017=335, EASL 2017=64, and BASL 2017=44) were screened for relevance ( Figure 1 ). Studies were included if they described effective practice or policy interventions in improving care generally 
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Practical steps to improve Hcv in people with OUD or for HCV specifically in people with a history of injecting drugs and OUD. Evidence from the literature review was then prioritized to identify most important practical steps to improve HCV care for people with OUD. Priorities were chosen by the authors (all with extensive clinical experience in HCV or OUD care) based on the opinion of potential impact. Interventions described in 57 studies, including 22 full research articles, 5 reviews, 23 abstracts/posters from conferences, and 7 consensus recommendations were chosen for analysis.
Results
A series of possible options for improving OUD care at each stage of the patient journey were defined based on an analysis of evidence obtained from the literature search and analysis (Table 2 ). Studies showing effective practical interventions for improving HCV care in such populations are summarized in Table 2 . Results are described according to steps on the patient journey.
Possible tactics to improve patient outcomes Engagement
Low engagement may be addressed by education programs: for patients, options include brief group sessions at drug treatment services including workshops, Q&A sessions, leaflets, videos on the basics of HCV and risk behaviors for transmission, HCV treatment pathway, right of equal access, 16, 17 and interactive digital health decision aids. 18 Education sessions for health care professionals (HCPs) directed in primary care 19 and drug treatment services, 17 and HCV awareness campaigns directed to the general public may be of benefit. Programs that actively seek patients such as pop-up and short-term services delivered by clinics in neighborhoods with high HCV prevalence are effective in promoting treatment engagement. 20 Developing strong provider-patient relationships improves outcomes by creating an "enabling environment" General terms related to Hcv care and opioid use disorder ("hepatitis c management" OR "hepatitis c treatment" OR "Hcv therapy" OR "treatment of chronic Hcv infection" OR "hepatitis c care" AND "People with a history of injecting drugs" OR "iDU" OR "PWiD" OR "Opioid Use Disorder" OR "opioid dependence" OR "opioid addiction" OR "intravenous drugs" OR "intravenous substance" OR "injecting drug" OR "injecting drug user" OR "heroin"). Additional keywords specific to patient journey: "hepatitis C patient presentation" OR "hepatitis C awareness" OR "hepatitis C engagement" OR "Hepatitis C screening" OR "hepatitis C diagnosis" OR "hepatitis C disease staging" OR "hepatitis C fibroscan" OR "hepatitis C workup" OR "assess for hepatitis c treatment" OR "hepatitis c referral" OR "hepatitis c specialist" OR "complete hepatitis c treatment" OR "hepatitis c treatment adherence" Abbreviation: Hcv, hepatitis c virus; iDU, injecting drug users; PWiD, people who inject drugs.
and avoiding stigma. 21, 22 Peer support improves engagement with medical interventions 23, 24 and can address potential mistrust and fear of discrimination. 25 screening Adoption of fast and effective screening methods improves efficiency. Dried blood spot testing (DBST) offers antibody testing and RNA confirmation in one step 26 and can be effectively implemented in drug treatment services, 27-29 alcohol clinics, prisons, needle equipment services, 28 or via out-reach mobile services. 30 A pretesting questionnaire-based screening tool helps identify people who may benefit most from testing in primary care. 31 Community-based active case finding with rapid antibody oral fluid test, either by peer facilitation 32 or by temporary clinics, 20 increases screening rate in high-risk populations. Targeted screening at general practices in areas of deprivation and high prevalence of injecting drug use, 33 or at drug treatment services, increases screening outcomes. For people with a history of injecting drugs who tested negative, it is important to offer routine testing every 12 months and following any high-risk injecting episode.
11,34
Work up/referral
Simplified work up with access to noninvasive methods such as transient elastography (TE) (also known as Fibroscan) and serum biomarker tests accelerates the workup process and enables triage for immediate care [35] [36] [37] implemented at drug treatment services, primary care, medically supervised injecting centers, 38 street-based outreach programs, or in prison. 37 Mobile TE further provides convenience in drug treatment services 29 or in mobile out-reach programs for hard-to-reach populations of drug users, prisoners, homeless, and psychiatric patients 30 or at primary care. 39 Noninvasive serum biomarker tests also eliminate many of the concerns associated with liver biopsy. 36 The aspartate aminotransferase-to-platelet ratio index (APRI), a calculated score predicting fibrosis, 37 is an effective prescreening tool to reduce the number of Abbreviations: APRi, aspartate aminotransferase-to-platelet ratio index; AUD, Australian dollars; DBst, dried blood spot testing; GP, general physician; HcPs, health care professionals; HBv, hepatitis B virus; Hcv, hepatitis c virus; iDU, injecting drug users; LDv/sOF/RBv, Ledipasvir/ sofobuvir/ Ribavirin; NHs, National Health system; OAt, opioid agonist therapy; Ost, opioid substitution therapy; OUD, opioid use disorder; PcPs, primary care physicians; PWiD, people who inject drugs; svR, sustained virologic response; sUD, substance use disorder; tE, transient elastography. patients requiring Fibroscan. 37 Logistic support such as tailored flexible scheduling facilitates work up completion. 40 A tailored approach with different options for engagement is most likely to be successful. 40 Referral processes can be facilitated by education for HCP at drug treatment services 17 and primary care; 19 support from peer mentors facilitates linkage to start HCV treatment. 41 
treatment
A single-location clinic with access to a multidisciplinary team is effective in facilitating the progression from patient identification to HCV treatment. 20, 42 Integrated HCV treatment can be provided at primary care, 39,43 drug treatment services, 39, 44 needle equipment services, 45 or prison. 46 It can be as a part of a traditional integrated treatment plan for OUD, 47, 48 or as a part of a combined program of integrated drug treatment, HCV, and needle equipment program, 49, 50 or for people who are actively injecting and not receiving integrated treatment for OUD. 45 Addiction specialists based in HCV clinics 51 or mobile teams for screening, diagnosis, and treatment may address underserved populations. 30 Wider prescribing options for DAA including primary care physicians (PCPs) increases treatment access; 43, 52, 53 treatment can be delivered in nurse-led drug treatment services, 39 
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Practical steps to improve Hcv in people with OUD Smartphone or desktop digital platforms assist clinical decision making and facilitate treatment initiation. 59 Teleconsultation is effective in overcoming physical barriers of having to meet with the HCV specialists. 60 Adherence to treatment can be facilitated with psychosocial support, such as continuous counseling, 61 case management services, actively screening for psychiatric comorbidities with referral to mental health providers including co-located specialists at HCV clinics and referral to peer-support groups with OUD care and buddy systems. Shorter treatment duration tailored to the population of injecting drug users may be effective. 62 Peer-led models combined with multidisciplinary care lead to improved knowledge, treatment uptake, and service provision. 23, 25 Contingency management, including monetary incentives, is effective in improving adherence to hepatitis B virus vaccination 63 and promotes HCV treatment initiation 41 among people with a history of injecting drugs. Developing or implementing existing national strategies, action plans, and guidelines for HCV treatment in people with a history of injecting drugs helps establish best practices. 64 Re-infection risk is limited by long-term follow-up with access to multidisciplinary care and harm reduction services after HCV treatment. [65] [66] [67] Regular HCV testing after the treatment and analysis of risk factors for re-infection is helpful for early engagement for potential interventions. 5, 11, 68, 69 Discussion DAA regimens offer the possibility of cure for HCV. People with a history of injecting drugs and OUD represent a major group requiring HCV treatment but find it hard to access care. It is the opinion of the authors that it is essential, now, to address limits to therapy access if HCV treatment uptake is to be available to all and eradication of the infection is to be achieved. Many citizens with great need for HCV therapy cannot navigate pathways to get the HCV care they need. Law, policy, and guidelines in many European countries defines the equality of access to health care for all citizens and increasingly for HCV treatment -it is the reality that despite this and if action is not taken, many with the greatest needs will not be able to access proven treatment for a serious condition.
This structured assessment identifies practical steps from published evidence, which can improve HCV care in people with a history of OUD. Recommendations for practical steps to improve care are shown in Figure 2 and summarized here:
1. Provide peer-led education for patients with OUD including updates on HCV and liver health, DAA therapy, right of equal access to therapy, and how to navigate treatment pathways. 17, 18, 70 2. Develop "enabling" provider-patient relationships 22, 71, 72 to support HCV treatment pathway navigation. • Make treatment easy with wide options for access to HCV care.
• Develop "enabling" providerpatient relationships; HCP active referral to support treatment pathway navigation
• Use supportive networks (eg peer-support, buddy systems, counselling) to encourage engagement 6. Make treatment easy with wide options for access to HCV care services. Implement wider prescription rights for PCP 43, 52 and care delivery by nurses and pharmacists in primary care, drug treatment services, and prison. 39, 43, 54, 57, 58 7. Provide integrated HCV care, 5, 11, 39, 42, 47, 51, 74 set up joint local working teams of HCP and administration from OUD, HCV, and PCP services focused on HCV treatment. 8. Review service results jointly to set standards of care and inform service development including "all under one roof " models and develop local guidelines to promote best practice. 64 9. Collect data to measure performance, indicate improvement potential, share results among local service providers and locations. 10. Ensure continuing access to harm reduction to prevent reinfection; provide regular testing after treatment for the early engagement of potential interventions. 5, 11, [66] [67] [68] 75 This recommendation is based on the clinical experience of clinicians with highly relevant long-term experience and interpretation of a review of current evidence. Evidence is collated from available published sources; this work is limited in this respect -in this evolving field, it is important to reconsider this work in the light of new evidence, in the future. Priorities are set based on clinical experience in Spain and observation of international practices. It is noted that the challenges for HCV and OUD treatment services are common in other countries 12 and that the wide range of models of care and experience in managing HCV in Spain and its regions may be representative of the approach in many other countries. This work identifies practical steps based on clinical factors; there are other social and provider-related factors outside the scope of this article that are important to address in this population.
Conclusion
People with a history of injecting drugs engaged with OUD care services often face considerable barriers for HCV care.
The recommendations advocated here for practical steps to improve care should be considered by all aiming to improve outcomes for marginalized populations who may find it difficult to access treatment for HCV.
Abbreviations
APRI, aspartate aminotransferase-to-platelet ratio index; DAA, direct-acting antiviral; DBST, dried blood spot testing; HCPs, health care professionals; HCV, hepatitis C virus; OAT, opioid agonist therapy; OST, opioid substitution therapy; OUD, opioid use disorder; PCPs, primary care physicians; TE, transient elastography; IDU, injecting drug users; PWID, people who inject drugs.
Dovepress
10
